1. Home
  2. DRMA vs UK Comparison

DRMA vs UK Comparison

Compare DRMA & UK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$2.16

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Logo Ucommune International Ltd

UK

Ucommune International Ltd

HOLD

Current Price

$0.80

Market Cap

1.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRMA
UK
Founded
2014
2015
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
1.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
DRMA
UK
Price
$2.16
$0.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
101.5K
17.3K
Earning Date
11-14-2025
12-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$20,463,860.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.13
$0.77
52 Week High
$23.70
$1.55

Technical Indicators

Market Signals
Indicator
DRMA
UK
Relative Strength Index (RSI) 30.68 31.48
Support Level $2.13 $0.81
Resistance Level $2.98 $1.01
Average True Range (ATR) 0.25 0.06
MACD -0.03 -0.02
Stochastic Oscillator 5.84 21.56

Price Performance

Historical Comparison
DRMA
UK

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

About UK Ucommune International Ltd

Ucommune International Ltd is a flexible office space provider and manager based in the People's Republic of China (PRC). The company offers long-term leasing, on-demand, and short-term leasing solutions to freelancers, start-up entrepreneurs, small and medium enterprises, and corporations. Company provide fully-serviced and well-furnished office spaces on a flexible basis. The members of the Ucommune community, which includes individuals and enterprises registered on the U bazaar mobile app, can avail of these services. The company has three operating segments: Workspace membership, Marketing and branding services, and Other services. Marketing and branding services generate the majority of the company's revenue.

Share on Social Networks: